Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AB Science S.A. (AB.PA)
Paris, FR
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.78% | +4.29% | -14.14% | -22.19% | -13.39% | -35.32% | -33.15% | -77.08% | -93.25% | -93.99% | -92.15% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+9.5% ★ Q4'25: +26.2% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+83.1% ★ Q4'25: +597.2% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-228.8% Q4'25: -53.1% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-103.7% Q4'25: -110.3% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q4'25: +11.0% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+17.3% Q4'25: +43.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.87× Q4'25: -0.36× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
917.0K
est: 913.5K (+0.4%)
|
1.10M
est: 2.44M (-54.7%)
|
1.34M
est: 1.25M (+7.0%)
|
1.93M
est: 2.23M (-13.4%)
|
2.10M
est: 2.06M (+1.7%)
|
2.28M
est: 2.30M (-0.7%)
|
1.51M
est: 1.55M (-2.7%)
|
1.74M
est: 8.99M (-80.7%)
|
1.70M
est: 63.01M (-97.3%)
|
1.57M
est: 1.60M (-1.8%)
|
1.58M
est: 1.80M (-12.1%)
|
1.61M
est: 1.60M (+0.4%)
|
958.0K
est: 1.60M (-40.1%)
|
970.0K
est: 1.08M (-10.4%)
|
1.07M
est: 1.10M (-2.5%)
|
1.17M
est: 1.10M (+6.7%)
|
1.20M
1.20M – 1.20M
+9.1% YoY
|
1.30M
1.30M – 1.30M
+8.3% YoY
|
1.40M
1.40M – 1.40M
+7.7% YoY
|
| EBITDA |
-8.87M
est: -913.5K (-871.2%)
|
-9.19M
est: -23.15M (+60.3%)
|
-10.17M
est: -4.93M (-106.1%)
|
-13.45M
est: -19.32M (+30.4%)
|
-14.92M
est: -13.61M (-9.6%)
|
-25.57M
est: -18.48M (-38.4%)
|
-29.60M
est: -27.74M (-6.7%)
|
-27.97M
est: -142.63M (+80.4%)
|
-28.27M
est: -91.61M (+69.1%)
|
-20.87M
est: -986.6K (-2,015.7%)
|
-17.10M
est: -21.45M (+20.3%)
|
-17.36M
est: -26.77M (+35.2%)
|
-13.41M
est: -1.60M (-738.0%)
|
-12.80M
est: -1.08M (-1,082.7%)
|
-4.92M
est: -34.29M (+85.7%)
|
-1.22M
est: -1.10M (-10.6%)
|
-1.20M
-1.20M – -1.20M
-9.1% YoY
|
-1.30M
-1.30M – -1.30M
-8.3% YoY
|
-1.40M
-1.40M – -1.40M
-7.7% YoY
|
| EBIT |
-9.59M
est: -913.5K (-949.7%)
|
-9.67M
est: -25.57M (+62.2%)
|
-10.37M
est: -5.40M (-92.1%)
|
-13.77M
est: -18.72M (+26.5%)
|
-14.92M
est: -12.73M (-17.3%)
|
-25.96M
est: -16.45M (-57.9%)
|
-27.23M
est: -25.96M (-4.9%)
|
-28.40M
est: -160.33M (+82.3%)
|
-26.06M
est: -97.07M (+73.2%)
|
-21.73M
est: -1.14M (-1,808.8%)
|
-18.19M
est: -18.09M (-0.5%)
|
-18.24M
est: -22.57M (+19.2%)
|
-14.21M
est: -1.60M (-788.3%)
|
-13.43M
est: -1.08M (-1,141.1%)
|
-5.58M
est: -28.91M (+80.7%)
|
-1.22M
est: -1.10M (-10.6%)
|
-1.20M
-1.20M – -1.20M
-9.1% YoY
|
-1.30M
-1.30M – -1.30M
-8.3% YoY
|
-1.40M
-1.40M – -1.40M
-7.7% YoY
|
| Net Income |
-9.49M
est: -17.92M (+47.1%)
|
-9.65M
est: -25.31M (+61.9%)
|
-10.99M
est: -5.36M (-104.9%)
|
-14.61M
est: -19.39M (+24.7%)
|
-16.11M
est: -13.50M (-19.3%)
|
-26.72M
est: -17.43M (-53.3%)
|
-27.70M
est: -26.72M (-3.7%)
|
-27.12M
est: -147.01M (+81.6%)
|
-26.06M
est: -92.69M (+71.9%)
|
-21.75M
est: -1.02M (-2,022.0%)
|
-15.05M
est: -22.51M (+33.2%)
|
-14.46M
est: -28.09M (+48.5%)
|
-13.62M
est: -16.89M (+19.4%)
|
-10.05M
est: -7.15M (-40.4%)
|
-7.83M
est: -8.54M (+8.3%)
|
-1.56M
est: -9.80M (+84.1%)
|
-8.57M
-8.57M – -8.57M
+12.5% YoY
|
-7.96M
-7.96M – -7.96M
+7.1% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
11.98M
est: 2.26M (+429.1%)
|
2.93M
est: 6.04M (-51.4%)
|
2.99M
est: 3.10M (-3.6%)
|
3.26M
est: 5.53M (-41.2%)
|
3.54M
est: 5.11M (-30.7%)
|
4.20M
est: 5.70M (-26.3%)
|
3.41M
est: 3.84M (-11.3%)
|
3.29M
est: 22.28M (-85.2%)
|
3.47M
est: 11.24M (-69.1%)
|
3.28M
est: 136.5K (+2,304.4%)
|
3.42M
est: 4.46M (-23.3%)
|
4.07M
est: 3.96M (+2.7%)
|
2.16M
est: 3.96M (-45.6%)
|
3.54M
est: 2.61M (+35.4%)
|
1.93M
est: 2.66M (-27.5%)
|
2.17M
est: 2.66M (-18.3%)
|
2.90M
2.90M – 2.90M
+9.1% YoY
|
3.14M
3.14M – 3.14M
+8.3% YoY
|
3.38M
3.38M – 3.38M
+7.7% YoY
|
| EPS |
-0.32
est: -0.34 (+6.8%)
|
-0.31
est: -0.40 (+22.3%)
|
-0.34
est: -0.47 (+28.2%)
|
-0.45
est: -0.57 (+21.3%)
|
-0.49
est: -0.51 (+4.2%)
|
-0.78
est: -0.63 (-24.8%)
|
-0.78
est: -0.82 (+4.9%)
|
-0.75
est: -0.82 (+8.7%)
|
-0.69
est: -0.62 (-11.3%)
|
-0.55
est: -0.68 (+18.5%)
|
-0.34
est: -0.32 (-6.3%)
|
-0.30
est: -0.32 (+6.3%)
|
-0.29
est: -0.29 (+0.0%)
|
-0.24
est: -0.12 (-105.4%)
|
-0.15
est: -0.41 (+63.4%)
|
-0.03
est: -0.16 (+84.1%)
|
-0.14
-0.14 – -0.14
+12.5% YoY
|
-0.13
-0.13 – -0.13
+7.1% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alain Moussy | Co-Founder, Chairman, President, Chief Executive Officer, MD & Scientific Director | 540.0K | male |
| Denis Gicquel | Executive Vice-President | 42.0K | male |
| Alexis BERNARD | Head of Veterinary Sales | — | male |
| Harshad KULKARNI | Head of Statistics | — | male |
| Laurent Guy | Chief Financial Officer | — | male |
| Christian FASSOTTE | Global Chief Medical Officer | — | male |
| Albert Ahn | President of USA Operations | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AB.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
